Type 1 Diabetes (T1D) Clinical Trials

Find Type 1 Diabetes (T1D) Clinical Trials Near You

Characterization of Autoreactive Regulatory and Conventional CD4 T Cells in Recent Onset Type 1 Diabetes and Control Individuals

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Type 1 diabetes (T1D) is caused by an autoimmune response leading to the destruction of pancreatic beta cells. The disease association with particular HLA class II alleles, particularly HLA-DQ8, indicates the implication of CD4 T cells in its aetiology. The hypothesis is therefore that T1D starts by the loss of tolerance in autoreactive CD4 T cells. This might result from alterations in conventional autoreactive CD4 T cells (Tcons), which drive disease, or autoreactive regulatory CD4 T cells expressing the transcription factor FOXP3 (Tregs), which normally maintain immune tolerance. The investigators expect that the characterization of HLA-DQ8-restricted Tcons and Tregs in recent onset HLA-DQ8+ T1D patients shall shed light on the molecular mechanisms underpinning T1D development. This knowledge will guide the development of novel cell therapies harnessing the power of genetically engineered Tregs expressing the relevant antigen receptor to restore immune homeostasis upon cell transfer. The ultimate goal is to reach a curative effect

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Maximum Age: 18
Healthy Volunteers: f
View:

⁃ Newly diagnosed T1DM group:

• Age ≥ 2 years and \< 18 years on day of inclusion;

• Weight ≥ 12 kg;

• Newly diagnosed T1DM, diagnosis defined according to International Society of Pediatric and Adolescent Diabetes (ISPAD) criteria by: hyperglycemia \> 2g/L and/or ketonemia and/or polyuro-polydipsia and/or weight loss ;

• Absence of other associated inflammatory or autoimmune diseases;

• Affiliation with a health insurance scheme or beneficiary (excluding AME);

• Written consent of parental guardians;

• Ability to understand and read French.

⁃ Control group :

• Age ≥ 2 years and \< 18 years on the day of inclusion;

• Weight ≥ 12 kg;

• No personal history of T1DM;

• Affiliation with a health insurance scheme or entitled person (excluding AME);

• Written consent from parental guardians;

• Ability to understand and read French.

Locations
Other Locations
France
Hôpital Necker Enfants Malades
RECRUITING
Paris
Contact Information
Primary
Jacques BELTRAND, MD, PhD
jacques.beltrand@aphp.fr
+33 1 40 61 53 20
Backup
Sarah BOUCHARD
sarah.bouchard@aphp.fr
+ 33 1 42 19 28 79
Time Frame
Start Date: 2025-05-06
Estimated Completion Date: 2027-05
Participants
Target number of participants: 80
Treatments
Other: Newly diagnosed T1DM group
children aged 2 to under 18 on the day of inclusion, with a recent diagnosis of type 1 diabetes
Other: Control group
children aged 2 to under 18 on the day of inclusion, with no history of type 1 diabetes
Related Therapeutic Areas
Sponsors
Collaborators: URC-CIC Paris Descartes Necker Cochin
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov

Similar Clinical Trials